Ipsen Gives Genfit Liver Drug New Lease Of Life
Pays €120m Upfront For Elafibranor Rights
The French biotech was firmly on the ropes last year after elafibranor joined the long list of failures for NASH but the promise it has shown in primary biliary cholangitis has persuaded Ipsen to part with a hefty upfront fee.
You may also be interested in...
Genfit CEO Pascal Prigent talks to Scrip about the company's high-profile trial failure in NASH and the pipeline pivot to various other drug candidates for rare liver diseases.
Focused on rare liver diseases such as acute-on-chronic liver failure following its 2020 disappointment in NASH, Genfit looks to become sector leader in ACLF and other indications such as hepatic encephalopathy.
After CEO David Loew declared again that Ipsen would be very active in the dealmaking space, Ipsen is paying $45m upfront to access two immuno-oncology candidates from Marengo and bagged an ERK inhibitor from AGV Discovery.